Business
CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update
Potentially pivotal Phase 2 trial of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) demonstrating rapid pace of enrollment
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"Potentially pivotal Phase 2 trial of Berubicin for the treatment of recurrent glioblastoma multiforme (GBM) demonstrating rapid pace of enrollment globallyCompany on track to report results of the pre-planned interim analysis in the third quarter of 2023HOUSTON, TX / ACCESSWIRE / April 3, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the full year ended December 31, 2022 and provided a clinical update of its anti-cancer drug candidate currently in development for the treatment of primary and metastatic brain and CNS cancer.\"Over the course of 2022, we made significant advancements in our ongoing clinical trial for Berubicin. We have expanded our clinical trial sites across Europe and continued with an encouraging and increasingly rapid pace of enrollment. As it currently stands, we are on track to reach our pre-planned interim analysis during the third quarter of 2023. We remain laser focused on moving this trial toward the finish line and importantly, potentially address the significant unmet need that currently exists for the treatment of GBM,\" commented John Climaco, CEO of CNS Pharmaceuticals. \"We are incredibly grateful to all stakeholders including our clinical staff for the continued support and execution. We believe 2023 is poised to be the most important year for the Company to-date and we continue to focus on the operational execution that will deliver the potential value-driving milestones in the near term.\"Berubicin HighlightsOngoing potentially pivotal trial evaluating lead product candidate Berubicin for the treatment of recurrent glioblastoma multiforme (GBM)The Company has opened 41 clinical trial sites of the 60 sites selected across the U.S., Italy, France, Spain, and Switzerland in its ongoing potentially pivotal study to evaluate efficacy of Berubicin in the treatment of adult GBM.A pre-planned, non-binding interim futility analysis will be conducted by an independent Data Safety Monitoring Board (DSMB) to recommend whether this study should continue as planned based on Berubicin showing value as a second-line treatment for patients with glioblastoma compared with Lomustine. The Co...